Clinical Trials Browser

Phase 2/3 × Interventional × Has announcements × Clear all

NCT04191499 2026-03-17

INAVO120

Phase 2/3 Active not recruiting

325 enrolled 14 charts 1 FDA

Breast Neoplasms

NCT02598661 2026-01-05

Study to Evaluate Imetelstat (GRN163L) in Participants With International Prognostic Scoring System (IPSS) Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)

Phase 2/3 Active not recruiting

289 enrolled 35 charts 1 FDA

Myelodysplastic Syndromes, Recurrence

NCT03022825 2025-10-16

QUILT-3.032: A Multicenter Clinical Trial of Intravesical Bacillus Calmette-Guerin (BCG) in Combination With ALT-803 (N-803) in Patients With BCG Unresponsive High Grade Non-Muscle Invasive Bladder Cancer

Phase 2/3 Active not recruiting

190 enrolled 1 FDA

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms

NCT03470922 2025-09-09

RELATIVITY-047

Phase 2/3 Active not recruiting

714 enrolled 17 charts 1 FDA

Melanoma, Neoplasms

NCT02784171 2024-12-10

Pembrolizumab in Patients With Advanced Malignant Pleural Mesothelioma

Phase 2/3 Completed

520 enrolled 16 charts 1 FDA

Other solid neoplasmThoracic

Mesothelioma

NCT04145531 2023-11-18

An Open-Label Study of JZP-458 (RC-P) in Patients With Acute Lymphoblastic Leukemia (ALL)/Lymphoblastic Lymphoma (LBL)

Phase 2/3 Completed

229 enrolled 17 charts 2 FDA

LymphoidOther hematologic neoplasm

Leukemia, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT01818492 2023-02-21

Study to Investigate Safety, Efficacy of an Anti-IFNγ mAb in Children With Primary Haemophagocytic Lymphohistiocytosis

Phase 2/3 Completed

45 enrolled 20 charts 1 FDA

Lymphohistiocytosis, Hemophagocytic

NCT02793583 2022-07-21

UNITY-NHL

Phase 2/3 Terminated

710 enrolled 1 FDA

LymphoidOther hematologic neoplasm

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell